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Summary
QUESTIONS UNDER STUDY: Deep brain stimulation
(DBS) has become a standard therapy for some forms of
severe movement disorders and is investigated for other
neurological and psychiatric disorders, although many sci-
entific, clinical and ethical issues are still open. We analyse
how the Swiss DBS community addresses these problem-
atic issues and future challenges.
METHODS: We have performed a survey among Swiss
DBS centres and a Delphi study with representatives of all
centres and further stakeholders related to the topic.
RESULTS: The current DBS infrastructure in Switzerland
consists of seven facilities. About 850–1,050 patients have
received a DBS system in Switzerland for various indica-
tions since its advent in 1976. Critical issues like patient
selection and dealing with side effects are in accordance
with international standards. There are indications of a con-
servative referral practice in Switzerland for DBS interven-
tions, but the data available do not allow verifying or refut-
ing this point.
CONCLUSIONS: Issues to investigate further are whether
or not there is an unmet medical need with respect to DBS,
long-term medical and psychosocial sequelae of the inter-
vention, conditions for enhancing the (research) collabor-
ation of Swiss DBS centers, and the effect of the recent
decision to reduce the number of DBS centres to 4 (resp.
possibly 3) on the potential of this therapeutic approach.
Key words: deep brain stimulation; Parkinson’s disease;
neuroethics; DBS infrastructure
Introduction
For several decades, chronic neurostimulation for thera-
peutic purposes was part of the options, neurosurgeons and
neurologists could offer to their patients [1]. Among these
options is deep brain stimulation (DBS), a technique that
can be traced back to the early 1950’s [2] (see fig. 1). Swiss
researchers have been actively involved in DBS develop-
ment. If the fraction of DBS papers compared to all neuros-
cience publications per country is taken as a measure for re-
search activity, Switzerland is among the 10 most product-
ive countries in DBS research [3]. Already in the 1940’s the
Swiss neurophysiologist Walter R. Hess, who performed
stimulation research in cats, spoke encouragingly about us-
ing this technique in patients [4, chapter 2]. The neurosur-
geon, Jean Siegfried started DBS in pain patients in 1976
(Jean Siegfried, personal communication, see methods sec-
tion) and performed in 1982 his first DBS intervention for
movement disorders in a dyskinesia patient [5, 6].
Figure 1
A schematic overview of the emergence of DBS summarising three
historical reviews about the history of deep brain stimulation [1, 2,
4: chapter 2] demonstrates that almost all modern applications of
DBS had precursors reaching back up to the 1950’s. The
stereotactic frame introduced by Ernst Spiegel and Henry Wycis in
1947 set the technological precondition for precisely addressing
targets deep in the brain. First, psychiatric applications have been
discussed and implemented – but they also had the longest delay,
probably due to the critique the experiments of José Delgado,
Robert Heath and others have raised at that time. Pain (beginning
in the late 1950’s, with a first culmination in the 1970’s; beside
others: Mazars and Hosobuchi) and epilepsy (beginning in the late
1970; beside others: Cooper) experienced a first appreciation as
diseases potentially suitable for DBS both before today’s re-
emergence. DBS for addressing movement disorders had been
experimentally approached already in the early 1960’s (beside
others: Alberts and Albe-Fessard) and were, although on low
profile, an ongoing issue within early DBS research before its
modern re-emergence marked by the paper of Benabid et al. [38].
The chart also shows the dates of official approvals of Medtronic
DBS-systems either by the European CE mark or by the Food and
Drug Administration (FDA) of the United States (data: Regina
Strasser, personal communication; HDE: Human Device
Excemption) and the founding dates of Swiss DBS centres
(compare with table 1).
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Since 2000, both the application of DBS and its appreci-
ation in the literature have grown remarkably [7]. Medtron-
ic – the leading DBS supplier – estimates that in January
2011 about 85,000 patients worldwide have obtained a
DBS intervention (Regina Strasser, personal communica-
tion; see methods section). Similar estimations account for
75,000 patients in spring 2010 [7] and 35,000 for late 2006
[8]. Because these numbers are based on sales statistics
(some sold DBS devices are replacements), they provide an
upper bound of 10’000 interventions per year. US-data in-
dicate that 2,500 to 3,000 patients obtain annually a DBS
system for Parkinson’s disease (PD) and essential tremor
(ET) in 200 to 250 US-centres [9], other data indicate even
more (approx. 4,000) interventions per year [10]. Extra-
polating these numbers to the “top-10” countries in DBS
research (which host approx. 430 centres; [3]) provides a
lower bound of 5,000 to 7,500 interventions per year glob-
ally. This conforms to other estimations of the annual ac-
crual of new patients per year worldwide (8,000–10,000;
[11]). These numbers are likely to increase, since DBS is
assessed for various novel neurological and psychiatric in-
dications, and because stimulation in established indica-
tions at an earlier time may be more beneficial for the pa-
tient [12], which decreases rejection probability due to ex-
clusion criteria. Up to date, DBS has been approved in PD,
ET, dystonia, epilepsy, and obsessive-compulsive disorder.
Current DBS research includes refractory depression, Tour-
ette syndrome, hypertension, Alzheimer’s disease, minim-
ally conscious state, obesity, memory impairment, severe
(auto-) aggressiveness, and drug addiction [13].
Economic data confirm the increasing appreciation of deep
brain stimulation. Currently, DBS involves about 1/6 of the
neuromodulation devices market with an estimated global
Figure 2
A simplified scheme of the basal-ganglia and thalamo-cortical
network responsible for movement control (based on [39, 40]).
Part a) shows the functional network, where red lines stand for
excitatory and blue lines for inhibitory connections. Part b) shows
the dysfunctional network resulting from a loss of dopaminergic
neurons in the Substantia nigra pars compacta (SNc). Network
nodes in red color indicate hyper-activation, nodes in blue color
hypo-activation. D1/D2: sub-populations of neurons in the striatum;
GPe: Globus pallidus externus; STN: Nucleus subthalamicus; GPi:
Globus pallidus internus; SNr: Substantia nigra pars reticulate;
PPN: Nucleus pedunculopontinus; Vim: ventral intermediate part of
Thalamus (Vim). Black arrowheads indicate potential DBS targets
in which quadripolar electrodes are stereotactically implanted. The
electrodes are connected to a pulse generator (usually placed
under the skin in the subclavicular or abdominal area) that controls
several parameters of the chronically applied electrical stimulation
(frequency, pulse width, and amplitude). The intervention is usually
made in the alert patient, as his active cooperation is required while
the electrodes are positioned for evaluating target accuracy and
stimulation benefit.
volume of 3 billion USD in 2010 [4, chapter 1]. Although
this market only represents 1% of the worldwide sales of
the global medical devices industry (300 billion USD in
2011, [14]), it is forecasted to grow at a Compound Annual
Growth Rate of 26.3 percent over the period of 2010–2014
[15]. Based on Medtronic’s sales, the annual growth rate
for DBS alone is 22% [16], which supports this estima-
tion. The DBS market leader Medtronic Inc. (Minneapolis,
USA) provides all necessary equipment for DBS interven-
tions (electrodes, wires, stimulators), although in the broad-
er field of stereotactic and functional surgical procedures
several other companies are active [17]. St. Jude Medical
has brought an approved DBS system (for PD) to the mar-
ket and at least one additional company (Boston Scientific)
will enter the DBS market in the next future. As Medtronic
started in 1997 the Swiss Manufacturing Operations in To-
lochenaz in the canton of Vaud, where all Medtronic DBS
systems are produced, Switzerland is currently the most
important global supplier for the DBS community.
Deep brain stimulation relied on experiences made in ablat-
ive surgery [4]. In movement disorders, such interventions
were the only option available for addressing severe symp-
toms before Levodopa and other medication were avail-
able. Movement disorders are still the most common in-
dications for DBS, in which subthalamic structures like
the Nucleus subthalamicus (STN), the Globus pallidus in-
ternus (GPi), the ventral intermediate part of Thalamus
(Vim), or the Nucleus pedunculopontinus (PPN) are tar-
geted (see fig. 2). As DBS involves surgical intervention
into the brain, it usually becomes an option for a patient,
when medication is not any more sufficient to control the
symptoms or has unbearable side effects like fluctuations
in movement quality. Compared to ablative surgery, DBS
has the advantage of being adjustable and reversible.
Whereas the beneficial effects of DBS on motor functions
are well established [18], its cognitive, affective and be-
havioural sequelae are increasingly discussed [7, 19, 20].
The evaluation of these sequelae is nontrivial, as they may
result from three causes: surgery, stimulation, or drug re-
duction. Furthermore, in the case of PD, one has to take
into account that similar effects may result both from dis-
ease progression as well as from medication. The spectrum
of cognitive, affective and behavioral side effects of DBS
is broad, but they are often transient or can be managed
through the adaptation of the stimulation parameters or by
psychotropic drugs. Some effects seem paradoxical: Af-
fective and social problems, especially in relationships and
work, may occur in spite of a good clinical outcome. Some-
times the changes are evaluated positively by the patients,
but negatively by their social surrounding, in particular if
these changes involve novelty seeking, risk willingness, or
sexual drive. Finally, DBS initialises a long-lasting rela-
tionship between the patient and medical specialists of sev-
eral disciplines. These factors make the ethical evaluation
of DBS interventions challenging.
With respect to DBS in Switzerland, an additional point is
important: The decision-making body of the inter-canton-
al agreement on highly specialised medicine has recently
decided (21 June 2011, [21]) to concentrate DBS in four
centres (Bern, Lausanne, St. Gallen, and Zurich; the latter
two might have to merge their activities in future according
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to a concentration concept to be elaborated). These centres
have to include all disciplines necessary for DBS interven-
tions, have to meet a minimal case load of 20 per year, and
have to establish a network with other clinics for patient se-
lection and long-term care. Furthermore, it demands build-
ing up a registry that includes all aspects of process and
results quality and to document and coordinate research
activities and teaching. The decision is limited in time until
2014 and will then be re-evaluated by the HSM project of-
fice.
Given this increasing appreciation of DBS as therapeutic
strategy for various indications, the medical and ethical
complexity of the intervention, and the recent decision to
manage the development of the DBS infrastructure in
Switzerland, we address in this contribution the following
questions:
1) How many DBS centres are currently active in
Switzerland, how many patients do they operate on per
year and for which indications, and how many patients
have been treated in Switzerland so far? Are these
numbers in accordance with the actual need, or is the
referral practice too conservative or too liberal?
2) How do the Swiss DBS centers deal with critical issues
like patient selection, sequelae, ensuring the quality of
the intervention, and alternatives to DBS?
Methods
For question one, we used a standardised questionnaire
that provides information on the numbers of interventions,
offered and planned indications, brain targets, disciplines
involved in assessment, and the start of the activity of the
centre. For question two, we utilised an interview scheme
that included the issues patient selection, dealing with side
effects, the quality of the intervention, and alternatives to
DBS. We interviewed active members of the DBS centres
that represent a core discipline involved in DBS (neuro-
logy, neurosurgery, or both).
From mid-2010 to mid-2011, the following representatives
of all Swiss DBS centres were interviewed by the first au-
thor face-to-face for approximately 60 to 120 minutes with
exception of the representative of Geneva, whose centre
just recently started its activity and where the interview was
performed by phone (in brackets: discipline, affiliation, and
date of interview): Ronald Bauer (neurosurgery, Canton-
al Hospital St. Gallen; 8 July 2011), Christian Baumann
(neurology, University Hospital Zurich; 27 April 2011),
Stefan Hägele-Link (neurology, Cantonal Hospital St. Gal-
len; 8 July 2011), Thomas Mindermann (neurosurgery,
Klinik im Park Zurich; 3 May 2011), Pierre Pollak (neur-
ology, University Hospital Geneva; 14 July 2011), Claudio
Pollo (neurosurgery, University Hospital Lausanne; 4
August 2011), Alexander Stibal (neurosurgery, Inselspital
Bern; 5 May 2011), Oguzkan Sürücü (neurosurgery,
University Hospital Zurich; 27 April 2011) and Ethan Taub
(neurosurgery, University Hospital Basel; 26 August
2010). The interviews were performed using a Delphi
methodology, i.e., the interview partners were invited to as-
sess and comment the results that emerged out of the in-
terrogation [22]. In this phase, we have included comments
from Michael Schüpbach (neurology, Inselspital Bern).
Based on the interviews, the questionnaire was completed
by us and sent to all centres for review and correction so
that the state of affairs by end of 2011 could be determined.
All centres with the exception of the Klinik im Park have
provided data.
To complement this research, the first author also inter-
viewed the following persons: Hans-Peter Ludin (neuro-
logy, former chairman of the research board of the Swiss
Parkinson Association; 5 July 2010), Adrian Merlo
(neurosurgery, president Swiss Society for Neurosurgery;
26 August 2010), Jean Siegfried (neurosurgery, former
physician at the University Hospital and the Klinik im Park
Zurich; 23 August 2010), and Regina Strasser (Product
Manager Medtronic Switzerland; 12 July 2010). We also
contacted the project office with respect to planning highly
specialised medicine in Switzerland (HSM) on 24 Septem-
ber 2011. Our goal was to obtain the report “Neurochirur-
gie in der Schweiz” dated from 3 May (to which the de-
cision [21] on concentrating DBS in Switzerland referred)
for having a basis of comparison of our own data. This re-
port has not been disclosed to us due to confidentiality reas-
ons. We then have posed some formal questions that have
been answered on 27 October 2011 by the HSM project
secretary. Those were partly incorporated in this contribu-
tion and have been crosschecked by the project secretary
on 23 November 2011.
Results
Quantitative survey
First, we present the data obtained by the questionnaire
(table 1): Switzerland has 6 DBS facilities based in public
hospitals (5 of them in university hospitals) and one in a
private hospital. A private clinic in Kreuzlingen (Eastern
part of Switzerland) also used to perform DBS interven-
tions, but is no longer active in this field (Christoph Ham-
burger, personal communication, 18 April 2011). Four
centres in public hospitals started their activity not before
2007, reflecting the global growth of the number of DBS
interventions in the last few years. Switzerland has one
centre per 1.12 m inhabitants, compared to one center per
1.70 m inhabitants in Germany (48 facilities currently offer
DBS in Germany; [3]). The implementation of the concen-
tration decision will raise the inhabitant-per-center-ratio to
1.97 m inhabitants per centre (4 centres) resp. 2.63 inhabit-
ants per centre (3 centres).
The current mean number of annual interventions is ap-
proximately 80 patients per year. This number is lower, but
in the same order as the data of the HSM project office (ap-
proximately 100 cases per year based on a survey made in
2010). The numbers of annual interventions per centre lie
between 3–5 (St. Gallen) and ~20 (Bern). Only one centre
(Bern) matches the minimal case load of 20 interventions
per year; that is requested by the concentration decision
[21] and that is considered as minimum for a training insti-
tution in DBS [23]. The current infrastructure would allow
operations on up to 200 patients per year. Whether the in-
frastructure is also sufficient for long-term clinical follow-
up (e.g., with respect to experts in neurology) is, according
Original article Swiss Med Wkly. 2012;142:w13570
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to the experts, less clear, as additional qualified personnel
in various fields may be required. The cumulative number
of patients that obtained DBS in Switzerland is in the or-
der of 650, including 119 patients that were operated on
at the University Hospital Zurich from 1976 to 1989 [24].
As no data from the Klinik im Park were available, we
took the implantations by Siegfried performed in the pion-
eer phase (13 years) as a lower bound and estimate (lin-
ear scaling) that at least 200 patients from 1989 to 2011
were operated on in this facility. Approximately 400 pa-
tients have been supervised by the “Klinik im Park” since
the early 1990s (Thomas Mindermann, personal commu-
nication); this number can be taken as an upper bound.
Therefore, the total number of patients who have obtained
DBS in Switzerland since its advent in the late 1970s (i.e.,
including DBS for pain) is about 850 to 1,050 patients.
In order to judge whether these numbers reflect the current
need or indicate either a conservative or a liberal referral
practice, the following information is required: data about
prevalence and incidence of the diseases which can be
treated by DBS, and the ratio of patients per disease for
which DBS is the best option. We investigated this point
only for PD, the major indication for DBS. Epidemiologic
studies on PD show large variations in incidence and pre-
valence estimations across countries [25], but reliable data
for Switzerland is missing (also according to the experts in-
terrogated). It can be estimated that the number of patients
that develop PD in Switzerland per year is between 1,000
to 2,000, which is validated by German sources that estim-
ate that 10,000 to 20,000 people develop PD per year [26,
27], whereas the German population is 10 times larger than
the Swiss population. Reliable data on the number of PD
patients who qualify for DBS are also missing. A survey
of Italian DBS centres referring to the selection procedure
almost 10 years ago (2002–2003) estimates that 1.6% to
4.5% of PD patients are eligible to STN-DBS [28]. But it
has been criticised that this study may considerably under-
estimate the ratio of PD patients who qualify for DBS [29].
In particular, the ratio would be higher, if patients would
be referred earlier to DBS [12], which seems to be a trend
in various centres [30]. The experts consulted by us estim-
ate the ratio of PD patients suitable for DBS by 10–20%.
Based on latter estimation and the prevalence estimations,
100 to 400 patients per year for PD alone may qualify for
DBS in Switzerland. Since the actual number of 80–100
DBS patients per year includes other conditions (e.g., dy-
stonia, ET, pain), the assignment practice in Switzerland
seems to be conservative, which is also the consensus opin-
ion of the DBS experts interviewed.
The Swiss DBS centres offer interventions for all indic-
ations that are currently approved for DBS (fig. 1, lower
part), although not every centre offers all of them. Treat-
ment of PD and ET is most common and available in all
centres. There is some disagreement regarding the optim-
al target between the experts: whereas several centres (e.g.,
Lausanne) prefer the STN in most cases, other centres more
often target also the GPi (in Bern in approximately 40% of
the cases) because of the larger probability of side-effects
in STN-DBS [31]. DBS interventions in pain, epilepsy, and
psychiatric indications (OCD, Tourette) are only offered in
selected centres, some are currently assessing to offer DBS
for refractory depression and other novel indications.
Qualitative interviews
As indicated in the introduction, there are various clinical
and ethical issues associated with DBS. Our interviews
confirmed that the Swiss DBS centres are aware of them:
All centres have established interdisciplinary teams for as-
sessing potential patients. These teams always include
neurologists, neurosurgeons, psychiatrists, and neuropsy-
chologists. Some centres also routinely include social
workers, care and rehabilitation specialists, physiotherap-
ists, occupational therapists and speech therapists. Family
members or other reference persons are always part of the
selection process. This process includes several (usually 2)
stages, although the practice of selection differs, e.g. the
procedure may require up to 7 days in hospital (St. Gal-
len). Patients suitable for DBS may wait up to 4 months for
surgery. In the majority of cases, the stimulation electrodes
are placed bilaterally, and the surgery (including placement
of the stimulator) is performed in one single session – al-
though variability in the detailed procedure due to indi-
vidual patient’s constitution is high.
Table 1: An overview of Swiss DBS centers which are currently operative. The column “start of current activity” refers to the year in which the first patient has been
operated at the center. The data reflect the situation by end of 2011.
Location Start of
current
activity
Current indications Planned indications # Patients /
year
Potential
# patients /
year
Total # of
patients
operated so far
Basel, University Hospital 2007 PD, ET, dystonia, MS tremor ~12 ~24 31
Bern, University Hospital 1996 PD, ET and other forms of tremor (MS, rubral),
chronic pain, dystonia, OCD, automutilation,
Tourette
Addiction, epilepsy,
headache, refractory
depression
~20 40–60 ~250
Geneva, University Hospital 2011 PD, ET, dystonia, epilepsy, MS tremor, Tourette Addiction, anorexia,
obesity, OCD, refractory
depression
~15 ~25 7*
Lausanne, University Hospital ~1995 PD, ET, chronic pain, dystonia, epilepsy Refractory depression 10–15 ~50 ~200
St. Gallen, Cantonal Hospital 2007 PD, ET, chronic pain 3–5 ~20 18
2009 PD, ET, dystonia, epilepsy, OCD Chronic pain, refractory
depression, Tourette
~15 20–25 31Zurich, University Hospital
1976–1989 119 [24]
Zurich, Klinik im Park 1989 PD, ET, chronic pain N/A N/A 200–400
* In Geneva, DBS surgery started in April 2011.
PD: Parkinson’s disease; ET: essential tremor; OCD: obsessive-compulsive disorders.
Original article Swiss Med Wkly. 2012;142:w13570
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The issue of unwanted side effects is well acknowledged
and a central issue in the selection process. This includes
both surgery-related adverse events and the impact on cog-
nition, mood and behaviour. Several options for minim-
ising the risk of side effects are used, e.g., selecting the GPi
as the target, especially in older patients, or intensifying
post-surgery supervision. Some experts observed in rare
cases “personality changes” of DBS patients that gave rise
to conflicting interpretations of the result (e.g., between the
patient and family members). In Bern, potential candid-
ates are explicitly directed to this issue and patients are in-
formed that in case of conflicting interpretations, the doctor
will have the right to change stimulation settings. The ex-
perts also confirmed to some degree the phenomenon of a
“satisfaction gap” [32] that may be present in particular in
PD patients. There is some disagreement between the ex-
perts regarding the amount of the benefit of DBS for indi-
vidual patients. Some suspect that the dissatisfaction rate
may be higher than reported in the literature, although no
quantitative evidence has been provided to support this ar-
gument.
There is no consensus among the experts which minimal
number of cases operated per year within a centre is ne-
cessary to ensure the quality of DBS interventions. Some
emphasised that a minimal number is necessary to keep the
quality of treatment at a high level. Others referred to the
training and experience of the experts involved as being the
more decisive parameter and considered the fixation of a
minimal case load as arbitrary to some degree. It has also
been argued that too many cases may interfere with build-
ing up a close relation to the patient, which is a necessary
condition for successful treatment. With respect to train-
ing, there is a consensus that DBS centres should include
professionals with long-term experience. For being a qual-
ified surgeon, a minimum of 200 DBS surgeries has been
mentioned, which is in accordance with the current train-
ing chart in movement disorders surgery [23]. The qual-
ification of the experts involved is a decisive element in
order to setup a DBS centre; e.g., for the avoidance of hard-
ware complications, for which the experience of the sur-
gical team is the main determinant [33], or with respect to
optimal DBS programming by the neurologist [34]. Obtain-
ing and maintaining qualified personnel is not an easy task
and so far has had a significant impact on centre activity. In
Bern, where the surgeon left the institution temporarily in
2003, patients were unwilling to move to other centres, as
long as the possibility to obtain surgery locally remained.
This is supported by the (mostly) localised patient catch-
ment areas of the Swiss DBS centres that have been repor-
ted to us.
Finally, regarding the issue of alternatives to DBS, some
disagreement between the experts is detected as well, in
particular regarding lesion procedures. Although no expert
suggested abolishing ablations completely, they disagreed
to what extent they might be a suitable option for some pa-
tients. The majority, however, was skeptical with respect to
the risks associated with lesion procedures (e.g., no revers-
ibility).
Discussion
Our study revealed several issues that require further atten-
tion: First, we have obtained expert opinion that the referral
practice in Switzerland for DBS interventions may be con-
servative, i.e., some patients do not get the optimal treat-
ment. However, this point needs further backing by more
solid data. In particular, one should investigate whether this
finding results from a justified skepticism regarding pos-
sible adverse effects of DBS, or whether it reflects lack of
knowledge or prejudice in the referring stakeholders and/
or patients. Research on this issue should complement the
current international discussion with respect to the optim-
al time window and criteria for referring patients to a DBS
centre.
Second, the Swiss DBS centers are aware of the many con-
troversial issues of DBS and consequentially they have de-
veloped a standard for patient management that partly ex-
ceeds international benchmarks (e.g., by including social
workers in the selection process or by addressing issues
of conflicting interpretation of therapy outcome). However,
there is still a need to assess the long-term benefit of the in-
tervention including evaluations by third parties (e.g., close
relatives) and cost-benefit comparisons. Given the cultur-
al diversity of the country, Switzerland may provide a suit-
able model to assess these issues. Therefore, we propose
advancing the collaboration between the DBS centres in
Switzerland for allowing for long-term follow-up studies
with higher case numbers involving psychosocial aspects.
When introducing a DBS case registry, it should allow for
comparison with nonsurgical patients to evaluate clinical
results as well as cost efficacy, since systematic assessment
and presentation of treatment results is a vital prerequis-
ite to reinforce the integration of surgical and nonsurgical
caregivers in a unified approach.
Third, DBS may be a promising tool for the therapy of
various diseases. However, alternatives should still be val-
ued as well. For example lesion procedures – performed
either by microsurgery or by radiosurgery (e.g., Gamma
Knife) – could remain an option for some special patient
groups, e.g., for patients who would be non-compliant with
the long-term follow-up after DBS, for patients who could
neither tolerate the stress of a wake-operation nor an oper-
ation under full anesthesia, and for patients who could not
accept any devices in their body (e.g., patients with obsess-
ive compulsion disorders, especially compulsive skin-pick-
ing, see [35, 36]). This opinion is supported by a recent ex-
pert consensus regarding DBS [37].
Finally, the reduction of the number of DBS centres in
Switzerland has been justified by ensuring the quality of
medical care. However, one has to take into account that
the reduction may also have effects that counteract this
goal: First, DBS interventions establish a long-term com-
mitment between a patient and an interdisciplinary team
of experts, requiring the build-up of close relationships
and regular contacts. This speaks in favour of more local-
ised centres. Second, the specifics of the intervention (e.g.,
with respect to the brain target, selection procedure, or pro-
fessionals involved in the interdisciplinary teams) lead to
different “cultures” in centres that reflect current discus-
sions in the global DBS community (e.g., whether STN
Original article Swiss Med Wkly. 2012;142:w13570
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still should be the “standard” target or not). Reducing the
number of centers affects this “cultural diversity” and may
lead to premature standardisations, limiting the choice of
patients. Third, the current state of research does not allow
for making reliable prognoses for the future development
of the number of patients suitable for DBS. If these num-
bers increase – which is likely given the various trends de-
scribed in the introduction, the annual case-load per centre
could reach 50 or more patients, requiring considerable in-
vestment in resources in the remaining centres. Whether
this will be realised is an open question given the cost pres-
sure many hospitals experience. Therefore, we suggest also
carefully investigating potential negative effects of concen-
trating DBS when the HSM decision will be re-evaluated
in 2014.
The last point gains importance with respect to research
for novel DBS applications as well as for technological
improvements, for which Switzerland is particularly suited
given its past achievements and the economic importance
of the DBS industry. With respect to research, a growing
case load in the remaining centres may have an ambivalent
effect. On the one hand, clinical research will be facilitated
as the number of potential subjects a researcher has directly
access to increases. On the other hand, a growing case load
for established DBS applications may hinder clinicians in-
vestigating novel applications due to restricted time re-
sources. We clearly agree with the principal aim of the
HSM decision that quality should be crucial for the de-
cision whether a DBS centre should stay operative or not.
Nevertheless, a transparent quality competition between
the centres may be better suited to fulfill this aim and is
also more compatible with the research process for estab-
lishing future application of DBS for patients with psychi-
atric and other neurological diseases.
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Figures (large format)
Figure 1
A schematic overview of the emergence of DBS summarising three historical reviews about the history of deep brain stimulation [1, 2, 4: chapter
2] demonstrates that almost all modern applications of DBS had precursors reaching back up to the 1950’s. The stereotactic frame introduced
by Ernst Spiegel and Henry Wycis in 1947 set the technological precondition for precisely addressing targets deep in the brain. First, psychiatric
applications have been discussed and implemented – but they also suffered the longest delay, probably due to the critique the experiments of
José Delgado, Robert Heath and others have raised at that time. Pain (beginning in the late 1950’s, with a first culmination in the 1970’s; beside
others: Mazars and Hosobuchi) and epilepsy (beginning in the late 1970; beside others: Cooper) experienced a first appreciation as diseases
potentially suitable for DBS both before today’s re-emergence. DBS for addressing movement disorders had been experimentally approached
already in the early 1960’s (beside others: Alberts and Albe-Fessard) and were, although on low profile, an ongoing issue within early DBS
research before its modern re-emergence marked by the paper of Benabid et al. [38]. The chart also shows the dates of official approvals of
Medtronic DBS-systems either by the European CE mark or by the Food and Drug Administration (FDA) of the United States (data: Regina
Strasser, personal communication; HDE: Human Device Excemption) and the founding dates of Swiss DBS centres (compare with table 1).
Figure 2
A simplified scheme of the basal-ganglia and thalamo-cortical network responsible for movement control (based on [39, 40]). Part a) shows the
functional network, where red lines stand for excitatory and blue lines for inhibitory connections. Part b) shows the dysfunctional network
resulting from a loss of dopaminergic neurons in the Substantia nigra pars compacta (SNc). Network nodes in red color indicate hyper-
activation, nodes in blue color hypo-activation. D1/D2: sub-populations of neurons in the striatum; GPe: Globus pallidus externus; STN: Nucleus
subthalamicus; GPi: Globus pallidus internus; SNr: Substantia nigra pars reticulate; PPN: Nucleus pedunculopontinus; Vim: ventral intermediate
part of Thalamus (Vim). Black arrowheads indicate potential DBS targets in which quadripolar electrodes are stereotactically implanted. The
electrodes are connected to a pulse generator (usually placed under the skin in the subclavicular or abdominal area) that controls several
parameters of the chronically applied electrical stimulation (frequency, pulse width, and amplitude). The intervention is usually made in the alert
patient, as active cooperation by the patient is required for evaluating target accuracy and stimulation benefit while the electrodes are
positioned.
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